

Many of you will be aware of the recent news article (on TVNZ over the weekend) about the Malaghan Institute's current study led by Dr La Flamme who is looking at whether two prescribed anti-psychotic drugs, low-dose Risperidone and Clozapine, can reduce symptoms and severity of MS. Currently the research has only taken place in laboratory models. Dr La Flamme is hoping to undertake a clinical trial to investigate this new therapeutic approach in patients within the next two years.

<http://tvnz.co.nz/national-news/multiple-sclerosis-breakthrough-video-5496475>

MSNZ and some of our Regional Societies have received some queries about this research including questions about how to sign up for the trial.

Our National Co ordinator has contacted the Malaghan Institute who have advised us that:

Currently the Malaghan Institute are actively seeking funding for a Phase 1 trial to confirm dose and do preliminary assessments on efficacy. They are also in the process of publishing pre clinical findings and once published it will be freely available. Until this time people are advised to visit the Malaghan Institute website (<http://www.malaghan.org.nz>) for more information.

<http://www.malaghan.org.nz/news-and-events/dr-anne-la-flamme-s-ms-research-featured-on-tvz-one-news/>

This is all the information we have at present but as more comes to light we will endeavour to update you.